Abstract:Objetive: To explore the characteristics of SMN1 gene variants and carry out functional verification for two children with Spinal muscular atrophy (SMA). Methods: Two male children with complicated SMA diagnosed at the Children's Hospital Affiliated to Capital Institute of Pediatrics respectively in July 2021 and April 2022 due to delayed or retrograde motor development were selected as the study subjects. Clinical data of the children were collected. Primary culture of skin fibroblasts was carried out, and peripheral blood samples were collected from both children and their parents. Multiplex ligation-dependent probe amplification, combined long-range PCR and nested PCR, and Sanger sequencing were carried out to detect the copy number and variants of the SMN1 gene. Absolute quantitative real-time PCR, Western blotting and immunofluorescence were used to determine the transcriptional level of the SMN gene, expression of the SMN protein, and the number of functional SMN protein complexes (gems body), respectively. This study was approved by the Children's Hospital Affiliated to Capital Institute of Pediatrics (Ethics No. SHERLLM2021009). Results: Child 1, a 1-year-old boy, was clinically diagnosed with type 1 SMA. Child 2, a 2-and-a-half-year-old boy, was clinically diagnosed with type 3 SMA. Both children were found to harbor a paternally derived SMN1 deletion and a maternally derived SMN1 gene variant, namely c.824G>T (p.Gly275Val) and c.884A>T (p.*295Leu). Compared with the normal controls and carriers, the levels of full-length SMN1 transcripts in their peripheral blood and skin fibroblast cell lines were significantly decreased (P < 0.05), and the levels of SMN protein normalized to that of β-actin, and the numbers of gems bodies in the primary fibroblast cells were also significantly lower (P < 0.05). Based on the guidelines from the American College of Medical Genetics and Genomics, both variants were classified as likely pathogenic (PS3+PM3+PM5+PP3; PS3+PM3+PM4+PP3). Following the diagnosis, both children had received nusinersen treatment. Although their motor function was improved, child 1 still died at the age of 2 due to severe pulmonary infection. The walking ability of child 2 was significantly improved, and his prognosis appeared to be good. Conclusion: Two cases of clinically complicated SMA have been confirmed by genetic testing and experimental studies, which has provided a reference for their accurate treatment.

The First Two Chinese Myhre Syndrome Patients with the Recurrent SMAD4 Pathogenic Variants: Functional Consequences and Clinical Diversity.

A Newborn Male with Myhre Syndrome, Hearing Loss, and Complete Syndactyly of Fingers 3–4

Myhre syndrome: A first familial recurrence and broadening of the phenotypic spectrum

Emergence of the natural history of Myhre syndrome: 47 patients evaluated in the Massachusetts General Hospital Myhre Syndrome Clinic (2016–2023)

Gain-of-Function Variants in SMAD4 Compromise Respiratory Epithelial Function

Prenatal Diagnosis of Myhre Syndrome in Two Cases: Further Delineation of the Cardiac and External Phenotype

Identification of 11 Potentially Relevant Gene Mutations Involved in Growth Retardation, Intellectual Disability, Joint Contracture, and Hepatopathy

First documented case of Myhre syndrome in Romania: A case report

Myhre syndrome in adulthood: clinical variability and emerging genotype-phenotype correlations

Identification of Two Novel MYH3 Variants Causing Different Phenotypes in Prenatal Diagnosis.

Prenatal and early diagnosis of Chinese 3-M syndrome patients with novel pathogenic variants.

Case Report: De Novo Variant in Myelin Regulatory Factor in a Chinese Child with 46,XY Disorder/difference of Sex Development, Cardiac and Urogenital Anomalies, and Short Stature

Case report: A novel splice-site mutation of MTX2 gene caused mandibuloacral dysplasia progeroid syndrome: the first report from China and literature review

Case Report: Improved Height in a Patient with Myhre Syndrome Using a Combination of Growth Hormone and Letrozole

SMAD4 mutations causing Myhre syndrome are under positive selection in the male germline

Further Delineation of Bone Marrow Failure Syndrome Caused by Novel Compound Heterozygous Variants of MYSM1.

[Clinical characteristics and genetics functional analysis of two children with Spinal muscular atrophy]

SMAD4 loss-of-function mutation predisposes to congenital heart disease.

Clinical and Genetic Analysis of Two Chinese Infants with Mabry Syndrome

SMAD1 Loss-of-Function Variant Responsible for Congenital Heart Disease

An Atypical Phenotype of a Patient with Infantile Spinal Muscular Atrophy with Respiratory Distress Type 1 (SMARD 1).